Kyle A Edgar

Author PubWeight™ 20.21^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Systematic generation of high-resolution deletion coverage of the Drosophila melanogaster genome.	Nat Genet	2004	8.24
2	A hierarchy of self-renewing tumor-initiating cell types in glioblastoma.	Cancer Cell	2010	3.34
3	Oncogenic ERBB3 mutations in human cancers.	Cancer Cell	2013	2.06
4	GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.	Mol Cancer Ther	2011	1.76
5	Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.	Drug Metab Dispos	2010	1.10
6	Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.	Sci Transl Med	2010	1.10
7	Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a β-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.	J Med Chem	2013	1.06
8	Targeting the PI3K pathway in the brain--efficacy of a PI3K inhibitor optimized to cross the blood-brain barrier.	Clin Cancer Res	2012	1.02
9	Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes.	PLoS One	2012	0.98